Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS)
Multiple myeloma (MM) is a blood cancer characterized by the proliferation of monoclonal plasma cells in the bone marrow, which leads to significant morbidity and mortality. MM is a life-threatening disease with debilitating symptoms of bone damage and pain, kidney failure, infections, and anemia. In the past two decades, there has been a rapid development of MM treatments and a subsequent change in drug efficacy, toxicity, long-term morbidities, and survival rates.1,2 The treatment decisions in MM patient population are increasingly guided by concerns about quality of life, achievement of cancer-free remission, living a longer overall survival, and a relentless search for a cure;3,4 however, the impact of these various decision-making factors on patients ’ actual therapy choices and the patients’ desire for cure and survival is mainly unknown.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Anastasiia Savchenko, Joseph D. Tariman, Alexandria Kohon, Shannon D. Simonovich, Thomas Dahan, Jessica Bishop-Royse Tags: Original Study Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Pain | Study | Toxicology | Urology & Nephrology